期刊档案
German Journal of Pharmaceuticals and Biomaterials
ISSN 2750-624X · eISSN 2750-6258 · German Journal of Pharmaceuticals and Biomaterials · Germany
German Journal of Pharmaceuticals and Biomaterials 钻石开放获取（无 APC），免版面费，投稿社区反馈审稿约 10 周，官网公布录用率 37%，2025 年发文 18 篇。
研究范围
研究范围与定位
German Journal of Pharmaceuticals and Biomaterials 由 German Journal of Pharmaceuticals and Biomaterials 出版。按 OpenAlex 近年发文统计，该刊主要发表 Advanced Drug Delivery Systems、Drug Solubulity and Delivery Systems、Medicinal Plant Research 等主题的论文，这 3 个主题约占 29.7%，主导子领域为 Pharmaceutical Science。（根据 OpenAlex 主题统计与中科院分区数据生成）
German Journal of Pharmaceuticals and Biomaterials (GJPB) [ p-ISSN: 2750-624X | e-ISSN:2750-6258 ] is an interdisciplinary peer-reviewed open access scientific journal that publishes high-quality experimental and theoretical research that contributes significantly to all aspects of pharmaceutical sciences and biomaterials and their related subjects including their applications in human (covering experimental and clinical therapeutics). The mission is to publish scientific work that has followed laborious methodologies and contribute to progress and development in pharmaceuticals and biomaterials. Scientific areas within the scope of this journal include but are not limited to pharmaceutics (all aspects of formulations and drug delivery systems, including oral, pulmonary, nasal, parenteral and transdermal delivery) and biopharmaceutics, including pharmaceutical biotechnology products, biochemistry and microbiology, pharmacology and toxicology, applied separation science (covers all areas of analytical/chromatography techniques), natural product drug discovery, medicinal chemistry, and bioactive polymers. This journal is also interested in work that addresses biomaterials but is not limited to covering all aspects of biomaterials with a broad range of physical, biological and chemical sciences that support the design of biomaterials and the clinical/scientific disciplines in which they are used. Country of Publication: GermanyFrequency: Quarterly (4 issues/year).
摘自期刊官网 Aims & Scope
编委会国家分布：未见中国大陆编委；主要国家 美国 2、德国 2、英国 1、日本 1、印度 1（共 13 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics12.1%
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics8.8%
- Medicinal Plant ResearchAgricultural and Biological Sciences8.8%
- Nanoparticle-Based Drug DeliveryMaterials Science6.6%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics6.6%
- Polysaccharides Composition and ApplicationsAgricultural and Biological Sciences5.5%
- Computational Drug Discovery MethodsComputer Science4.4%
- Essential Oils and Antimicrobial ActivityAgricultural and Biological Sciences4.4%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）未收录
该期刊未被此版本分区表收录。
《新锐期刊分区表》（ 2026年3月发布）未收录
该期刊未被此版本分区表收录。
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
数据库收录
DOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- h-index
- 5OpenAlex ·
- i10-index
- 2OpenAlex ·
- 两年平均被引
- 0.79OpenAlex ·
- Gold OA 文章占比
- 0%LetPub ·
发文规模
- 年发文量（出版商公布）
- 4出版商官网 ·
逐年发文量 OpenAlex 统计 · 累计 73 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 4 | 4 | 30 |
| 2025 | 18 | 18 | 50 |
| 2024 | 17 | 17 | 35 |
| 2023 | 17 | 17 | 24 |
| 2022 | 17 | 17 | 5 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
- 平均审稿速度（社区反馈）
- 10 WeeksLetPub ·
- 录用率（出版商公布）
- 37%出版商官网 ·
- 投稿到发表（期刊自报）
- 约 10 周DOAJ ·
- 评审方式
- 双盲同行评审DOAJ
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
钻石开放获取（无 APC）DOAJ
所有文章开放获取，且不向作者收取文章处理费。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | 无文章处理费 | 无 | CC BY | |
| LetPub | 无文章处理费 | 无 | — | |
| 出版商官网 | 无文章处理费 | — | — |
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点4 项，摘自作者指南
- 首次投稿格式
- 允许不按期刊格式排版（free format）
- 推荐审稿人
- 必须提供
- 图文摘要
- 必须提供
- 投稿信（Cover letter）
- 必须提供
接收的文章类型12 种
- case reportThe Editorial Board considers the following types of paper: Letters, Research Articles, Original Articles, Review Articles (including Mini-reviews and Critical …未说明篇幅
- case studyThe Editorial Board considers the following types of paper: Letters, Research Articles, Original Articles, Review Articles (including Mini-reviews and Critical …未说明篇幅
- commentaryThe Editorial Board considers the following types of paper: Letters, Research Articles, Original Articles, Review Articles (including Mini-reviews and Critical …未说明篇幅
- editorialThe Editorial Board considers the following types of paper: Letters, Research Articles, Original Articles, Review Articles (including Mini-reviews and Critical …未说明篇幅
- letterThe Editorial Board considers the following types of paper: Letters, Research Articles, Original Articles, Review Articles (including Mini-reviews and Critical …未说明篇幅
- opinionThe Editorial Board considers the following types of paper: Letters, Research Articles, Original Articles, Review Articles (including Mini-reviews and Critical …未说明篇幅
- original articleThe Editorial Board considers the following types of paper: Letters, Research Articles, Original Articles, Review Articles (including Mini-reviews and Critical …未说明篇幅
- research articleThe Editorial Board considers the following types of paper: Letters, Research Articles, Original Articles, Review Articles (including Mini-reviews and Critical …未说明篇幅
- research reportThe Editorial Board considers the following types of paper: Letters, Research Articles, Original Articles, Review Articles (including Mini-reviews and Critical …未说明篇幅
- reviewThe Editorial Board considers the following types of paper: Letters, Research Articles, Original Articles, Review Articles (including Mini-reviews and Critical …未说明篇幅
- review articleThe Editorial Board considers the following types of paper: Letters, Research Articles, Original Articles, Review Articles (including Mini-reviews and Critical …未说明篇幅
- short communicationThe Editorial Board considers the following types of paper: Letters, Research Articles, Original Articles, Review Articles (including Mini-reviews and Critical …未说明篇幅
官网政策摘录作者资格、利益冲突、同行评审、查重
- 作者资格 Authorship/Author Disclosure
署名政策：稿件中的所有作者对传达给期刊的技术信息负有同等责任，所有署名作者必须阅读并批准最终版本，且必须对研究设计、数据分析或论文撰写做出积极贡献并批判性审阅内容；仅参与经费获取或数据收集不能作为署名理由。 模型中文摘要
All the authors in a manuscript are equally responsible for the technical information communicated to the journal. Thus, it is necessary that all authors must read and approve the final version of the manuscript before submitting it to the journal. All named authors must have made an active contribution to the conception and design and/or analysis and interpretation of the data and/or the drafting…
原文 ↗出版商官网 ·- 利益冲突 Authorship/Author Disclosure
利益冲突政策：稿件中的所有作者对传达给期刊的技术信息负有同等责任，所有署名作者必须阅读并批准最终版本，且必须对研究设计、数据分析或论文撰写做出积极贡献并批判性审阅内容；仅参与经费获取或数据收集不能作为署名理由。 模型中文摘要
All the authors in a manuscript are equally responsible for the technical information communicated to the journal. Thus, it is necessary that all authors must read and approve the final version of the manuscript before submitting it to the journal. All named authors must have made an active contribution to the conception and design and/or analysis and interpretation of the data and/or the drafting…
原文 ↗出版商官网 ·- 同行评审 Peer-Review
同行评审政策：通过初审和编辑评估的稿件将进行双盲同行评审，由至少两名相关领域专家进行评估，评审人的身份将保密。 模型中文摘要
If a manuscript is successful in making it through the initial check and desk review, it is next sent for double-blind peer review. The article will be evaluated by a minimum of two experts in the relevant subject area, both of whose identities will be kept confidential (double-blind peer-review process). Kindly refer to our policies regarding peer review.
原文 ↗出版商官网 ·- 查重
抄袭政策：期刊将使用iThenticate（在线抄袭检测软件）对提交的文章进行抄袭检查。 模型中文摘要
iThenticate (online plagiarism detection software) will be used to perform a plagiarism check on the articles that are submitted.
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- German Journal of Pharmaceuticals and Biomaterials
- 出版国家或地区
- Germany
- 出版语言
- English
- ISSN
- 2750-624X
- 电子版 ISSN
- 2750-6258
- 官网最新一期
- Volume 4, Issue 4（2025 年）
- 官方链接
- 期刊主页 ↗OpenAlex
- 作者指南 ↗LetPub
- Aims & Scope ↗LetPub
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗LetPub
- 编委会 ↗LetPub
- 查重政策 ↗DOAJ
常见问题
关于 German Journal of Pharmaceuticals and Biomaterials 的常见问题
German Journal of Pharmaceuticals and Biomaterials 的审稿周期多长？
投稿社区反馈的平均审稿速度为约 10 周；期刊官网公布的录用率为 37%。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
German Journal of Pharmaceuticals and Biomaterials 的投稿格式要求是什么？
据期刊作者指南：首次投稿格式：允许不按期刊格式排版（free format）；推荐审稿人：必须提供；图文摘要：必须提供；投稿信：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
German Journal of Pharmaceuticals and Biomaterials 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 13 位编委中，没有中国大陆学者；人数最多的国家是 美国（2 位）、德国（2 位）、英国（1 位）。统计按编委会页面列出的机构国家计，仅供参考。
German Journal of Pharmaceuticals and Biomaterials 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，German Journal of Pharmaceuticals and Biomaterials 被 DOAJ 收录。
German Journal of Pharmaceuticals and Biomaterials 是开放获取期刊吗？版面费多少？
German Journal of Pharmaceuticals and Biomaterials 为钻石开放获取（无 APC）。不收取文章处理费。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex、DOAJ；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-25 归档）。最近更新：。